Annals of the Rheumatic Diseases最新文献

{"title":"Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study.","authors":"Emily Rayens, Lina S Sy, Lei Qian, Jun Wu, Bradley K Ackerson, Yi Luo, Yanjun Cheng, Antony T Lin, Zendi Solano, Justine De Jesus, Britta Amundsen, Ana Florea, Jennifer H Ku, Elizabeth Chmielewski-Yee, Driss Oraichi, Harry Seifert, Huifeng Yun, Hung Fu Tseng","doi":"10.1016/j.ard.2025.01.045","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.045","url":null,"abstract":"<p><strong>Objectives: </strong>In an interim analysis, we evaluated vaccine effectiveness (VE) against herpes zoster (HZ) and postherpetic neuralgia (PHN) and safety of recombinant zoster vaccine (RZV) in adults aged ≥50 years with rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>VE was assessed using a retrospective matched cohort analysis of Kaiser Permanente Southern California members aged ≥50 years with RA receiving 2 RZV doses (≥4 weeks apart) and matched up to 1:3 to RZV-unvaccinated individuals. Stratified Cox proportional hazards regression was used to estimate adjusted hazard ratios and VE against HZ and PHN. Safety was assessed using a self-controlled case series analysis of chart-confirmed RA flare within 30 days after any RZV vaccination versus comparison periods. The relative risk (RR) was estimated using conditional Poisson regression.</p><p><strong>Results: </strong>In adults ≥50 years with RA (2-dose vaccinated: 1926; unvaccinated: 5746), the adjusted VE of 2 RZV doses against HZ was 60.7% (95% CI, 41.0%-73.8%); in a subgroup analysis among those who received 2 doses 4 weeks to 6 months apart, VE against HZ was 57.9% (95% CI, 34.4%-73.0%). Adjusted VE of 2 RZV doses against PHN was 88.7% (95% CI, 12.1%-98.5%). Among 2606 adults with RA who received ≥1 RZV dose, no increased risk of RA flares within 30 days after RZV vaccination was observed (RR, 1.02; 95% CI, 0.75-1.37).</p><p><strong>Conclusions: </strong>Among adults ≥50 years with RA, 2 RZV doses provided protection against HZ and PHN. The study did not observe an increased risk of RA flares within 30 days following RZV vaccination.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing the number of minor salivary glands from patients with Sjögren's disease improves the diagnostic and measurement precision of the histological focus score.","authors":"Konstantinos Tryposkiadis, Saba Nayar, Valentina Pucino, Charlotte G Smith, Rachel M Brown, Timothy Bates, Simon J Bowman, Alice Sitch, Malcolm Price, Francesca Barone, Jon Deeks, Benjamin A Fisher","doi":"10.1016/j.ard.2025.01.038","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.038","url":null,"abstract":"<p><strong>Objectives: </strong>Minor salivary gland (MSG) biopsy has an important role in Sjögren's disease diagnosis and research. MSGs show within-patient variation in number of lymphocytic foci per unit area, but the optimal number of MSGs required to balance reproducibility and clinical acceptability has not been determined.</p><p><strong>Methods: </strong>Monte Carlo simulations were performed to investigate impact of MSG number on (i) diagnosis based on focus score (FS) ≥1; (ii) reproducibility, defined as the extent to which 2 FS measurements obtained from 2 within-patient biopsies are the same, assuming no systematic differences have occurred in between biopsies; and (iii) smallest sample size required to detect a clinically meaningful difference in FS. Data simulation was repeated for different MSG numbers (range, 2-7).</p><p><strong>Results: </strong>Higher reproducibility was noted for every unit increase in MSG number, with the median absolute difference between 2 within-patient FS measurements decreasing from 1.05 (SD = 0.25) with 2 glands to 0.52 (SD = 0.12) with 7 glands. MSG number influenced the probability of a simulated patient receiving a FS ≥1, increasing from a median of 0.67 with 2 glands to 0.77 with ≥5 glands. MSG number influenced clinical trial sample sizes. For example, 80% statistical power to detect a 40% FS reduction required a sample size per group of 62 with 2 glands and 25 with 7 glands.</p><p><strong>Conclusions: </strong>For a diagnostic threshold of FS ≥1, a minimum of 5 glands should ideally be targeted. For continuous FS values, a larger number of MSGs (eg, 6) will increase reproducibility further and reduce clinical trial sample size requirements.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis.","authors":"Viktor Molander, Hannah Bower, Thomas Frisell, Johan Askling","doi":"10.1016/j.ard.2025.01.020","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.020","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate rates of key safety outcomes in patients with rheumatoid arthritis (RA) initiating biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and in reference cohorts, presented over time since the market entry of each b/tsDMARD class and over calendar period at treatment start.</p><p><strong>Methods: </strong>This was a nationwide register-based cohort study conducted from 2006 to 2022. From the Swedish Rheumatology Quality Register and national registers, we identified treatment initiators of b/tsDMARDs (n = 33,550 initiations), an early bionaive RA cohort (n = 16,011), and a matched general population cohort (n = 111,074). The main outcome was first of either major adverse cardiovascular event, venous thromboembolism, cancer, or serious infection. We stratified rates by time since market entry of each b/tsDMARD class at treatment start, and by calendar year of treatment start. We calculated incidence rates (IRs) and hazard ratios (HRs) using Cox regression and adjusted for patient characteristics.</p><p><strong>Results: </strong>Overall, 5862 events were observed in the b/tsDMARD initiator cohort. b/tsDMARD treatments initiated >5 (vs <2) years since market entry of that class were associated with lower outcome rates (unadjusted HR = 0.74; 95% CI = 0.67-0.81). This association was attenuated once adjusting for patient characteristics (adjusted HR = 0.93; 95% CI = 0.84-1.03). By contrast, during our study period, adjusted rates declined (adjusted HR = 0.74 and 95% CI = 0.69-0.80 for b/tsDMARDs initiated 2016-2021 vs 2006-2010), despite a constant rate in the background population.</p><p><strong>Conclusions: </strong>Modest channelling makes the safety profile of b/tsDMARDs appear worse when new on the market. Declining incidences of typical RA comorbidities in b/tsDMARD initiators during recent years suggest that the bar defining an \"acceptable\" safety profile for new b/tsDMARDs for use in RA should be lower(ed).</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study.","authors":"Yu Chen, Cong Ye, Pingting Yang, Wen Zhang, Lie Dai, Wei Wei, Rui Wu, Shuang Ding, Lefeng Chen, Xiuhua Wu, Jun Zhao, Chengqian Liao, Wei Sun, Hisanori Umehara, Shaozhe Cai, Lingli Dong","doi":"10.1016/j.ard.2025.01.033","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.033","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the effects of thalidomide in preventing disease relapse with 'zero' glucocorticoids (GCs) usage in IgG4-related disease (IgG4-RD).</p><p><strong>Methods: </strong>This was a multicentre, randomised, double-blinded, placebo-controlled study, in which eligible patients in disease active status were randomised into 2 groups (group 1: GCs+Thalidomide; group 2: GCs+Placebo) at a 1:1 ratio. The primary outcome of this trial was the disease relapse rate at month 12, whereas the secondary outcomes were the disease remission rate at month 12 and the incidence of adverse events (AEs).</p><p><strong>Results: </strong>A total of 60 patients were randomised, and 57 patients (GCs+Thalidomide: 29; GCs+Placebo: 28) finished the study per protocol. The relapse rates of the GCs+Thalidomide and GCs+Placebo groups at month 12 were 13.8% and 67.8%, respectively. A 100% response rate was observed in both treatment group, while the remission rates of the GCs+Thalidomide and GCs+Placebo groups were 75.8% and 32.1%, respectively. In total. 49 AEs were recorded in 35 participants, in which 4 were graded as moderate, and 45 were graded as mild. The risk-benefit analysis based on the evaluation of rates of disease relapse and moderate AEs within the 12-month follow-up showed a NNT (number needed to treat) of 2 and a NNH (number needed to harm) of 8 for thalidomide treatment.</p><p><strong>Conclusions: </strong>Thalidomide can effectively prevent relapse in IgG4-RD outweighing its side effects, which indicating that thalidomide can be a potential safe therapeutic option for disease relapse prevention in parallel with steroid sparing in IgG4-RD.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to treat undifferentiated arthritis today or tomorrow? A consideration of treatment recommendations in light of current evidence.","authors":"Annette H M van der Helm-van Mil, Daniel Aletaha","doi":"10.1016/j.ard.2025.01.036","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.036","url":null,"abstract":"<p><p>Patients with undifferentiated arthritis (UA) have clinically apparent inflammatory arthritis but no evident diagnosis or classification. Considering UA as a definition 'per exclusionem' implies that the population designated by this term is affected by changes in the way other diseases, eg, rheumatoid arthritis (RA), are classified or diagnosed. Current treatment recommendations for UA are largely similar to recommendations for RA. The recommendations are based on the idea that UA is an early stage of RA and on literature generated in the 2000s before the development of the 2010 classification criteria for RA. However, conventional UA (so-called '1987-UA') is presumably different than contemporary UA ('2010-UA'). Strikingly, there are no randomised placebo-controlled trials done on '2010-UA,' and this poses questions on whether the recommendations for UA are still valid. In this absence, we assume that treatment recommendations from '1987-UA' can be extrapolated to '2010-UA' if (1) essential patient characteristics are the same, (2) long-term outcomes are similar, (3) prognostic factors are largely the same, and (4) there are indications from research other than placebo-controlled randomized clinical trials (RCTs) that disease modifying antirheumatic drug (DMARD) treatment in 2010-UA is effective. We evaluate these requirements one by one based on the literature on 2010-UA. This reveals that 2010-UA is milder in initial presentation and disease outcomes than 1987-UA. Today's UA population is >95% anticitrullinated protein antibody-negative, presents with mono- or oligoarthritis, frequently achieves spontaneous remission, and rarely progresses to RA. We suggest that 2010-UA is a distinct patient group within the early arthritis spectrum, requiring additional research, after which recommendations may need to be updated.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort.","authors":"Giulia Frazzei, Robert B M Landewé, Carlijn Wagenaar, Lotte A van de Stadt, Dirkjan van Schaardenburg, Sander W Tas, Ronald F van Vollenhoven","doi":"10.1016/j.ard.2025.01.042","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.042","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to predict rheumatoid arthritis (RA) development in a cohort of at-risk individuals with arthralgia positive for anti-citrullinated protein antibodies (ACPA) and/or rheumatoid factor (IgM-RF), followed for up to 5 years.</p><p><strong>Methods: </strong>In total, 617 seropositive arthralgia individuals were included in the study. The ability of clinically and biologically relevant baseline characteristics to predict RA development was assessed using Cox proportional hazard regression analysis.</p><p><strong>Results: </strong>Thirty-eight percent of study population was IgM-RF-positive, 31% was ACPA-positive, and 30% was positive for both ACPA and IgM-RF. Mean (SD) time till arthritis was 19.6 (19.0) months in 33.7% of participants; mean (SD) follow-up time of individuals who did not develop arthritis was 47.3 (24.5) months. We found that first-degree relatives of RA (hazard ratio [HR] = 1.50), individuals who had intermittent symptoms (HR = 1.64), symptoms for less than 12 months at inclusion (HR for symptom duration >12 months = 0.71), morning stiffness ≥1 hour (HR = 1.63), or reported joint swelling (HR = 1.51) independently had higher risk to develop arthritis. Moreover, individuals with high ACPA titres (HR = 4.65) or double positivity for ACPA and IgM-RF (HR = 6.83) had the highest risk of developing RA, as compared to those with only IgM-RF or low ACPA titres. The risk of developing arthritis was 58.2% when at least 3 variables were present.</p><p><strong>Conclusions: </strong>Baseline characteristics can be used to predict future RA development in seropositive arthralgia individuals. These results will aid in the identification of individuals at highest risk of developing RA, who could potentially benefit from additional follow-ups in clinical practice and recruitment in preventive trials.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methotrexate osteopathy: an increasingly recognised condition manageable only through methotrexate discontinuation.","authors":"Tim Rolvien","doi":"10.1016/j.ard.2025.01.041","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.041","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force.","authors":"Veronika Rypdal, Hermine I Brunner, Brian M Feldman, Nicolino Ruperto, Amita Aggarwal, Sheila T Angeles-Han, Maria Backström, Erin Balay-Dustrude, Claudia Bracaglia, Fabrizio De Benedetti, Pavla Doležalová, Marco Garrone, Jaime Guzman, Daniel B Horton, Ronald M Laxer, Daniel J Lovell, Tonje Løvli, Silvia Magni-Manzoni, Francesca Minoia, Esi M Morgan, Jane Munro, Ellen B Nordal, Christophe Normand, Nancy Pan, Elisa Patrone, Angelo Ravelli, Claudia Saad Magalhães, Rashmi Sinha, Joost F Swart, Maarit Tarkiainen, Marinka Twilt, Paula Vähäsalo, Sebastiaan Vastert, Jelena Vojinovic, Pamela F Weiss, Beth Gottlieb, Alessandro Consolaro","doi":"10.1016/j.ard.2025.01.013","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.013","url":null,"abstract":"<p><strong>Objectives: </strong>To develop consensus-based recommendations for physician's global assessment of disease activity (PhGA) scoring and to standardise definitions of disease activity.</p><p><strong>Methods: </strong>An international task force of 34 members was assembled, and recommendations were developed in 3 phases: (1) 2 preliminary surveys of paediatric rheumatologists and a literature review; (2) 14 videoconference meetings, informed by multicriteria decision analysis and formal anonymous voting; and (3) a 2-day in-person consensus conference using structured nominal group technique discussions and formal voting. The threshold for achieving consensus was ≥78% of voting task force members. Agreement with the final statements was rated using a numerical rating scale from 0, strongly disagree, to 10, strongly agree.</p><p><strong>Results: </strong>Eighteen points to consider were agreed upon. All statements achieved consensus (≥78%), with a level of agreement ≥9.2. Points included the definition of disease activity in juvenile idiopathic arthritis (JIA), factors to assess in nonsystemic JIA and systemic JIA, consideration of available imaging and laboratory tests, the role of extra-articular manifestations, the evaluation of treatment, and the timing of PhGA scoring.</p><p><strong>Conclusions: </strong>The task force developed consensus-based recommendations when scoring the PhGA in nonsystemic and systemic JIA. These recommendations will lead to more reliable scoring of disease activity in patients with JIA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis.","authors":"Denis Poddubnyy, Victoria Navarro-Compán, Murat Torgutalp, Suzanne Arends, Sibel Zehra Aydin, Simone Battista, Filip van den Bosch, Christine Bundy, Alberto Cauli, Jo Davies, Maxime Dougados, Tuncay Duruöz, Bassel El-Zorkany, Warren Fong, Floris van Gaalen, Rodrigo Garcia-Salinas, Marco Garrido Cumbrera, Pál Géher, Lianne Gensler, Simeon Grazio, Feng Huang, Mitsumasa Kishimoto, Robert Landewé, Ying Ying Leung, Pedro M Machado, Helena Marzo-Ortega, Bhowmik Meghnathi, Anna Molto, Elena Nikiphorou, Sofia Ramiro, Martin Rudwaleit, Carla G S Saad, Alexandre Sepriano, James Wei, Xenofon Baraliakos, Désirée van der Heijde","doi":"10.1016/j.ard.2025.01.035","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.035","url":null,"abstract":"<p><strong>Objectives: </strong>To develop a consensus-based expert definition of difficult-to-manage (D2M) axial spondyloarthritis (axSpA), incorporating treatment-refractory (TR) disease.</p><p><strong>Methods: </strong>A literature review was conducted in 2022 to identify potential definitions for D2M/TR axSpA from prior studies, followed by a 2-round Delphi consensus process conducted in 2022 and 2023 to identify components of D2M axSpA. Based on the results of the Delphi process, a draft of the D2M axSpA definition was developed and presented to the expert task force, including patient representation, and, subsequently, to the Assessment of SpondyloArthritis International Society (ASAS) membership for endorsement in January 2024.</p><p><strong>Results: </strong>Consensus was reached on a D2M definition encapsulating treatment failure (treatment according to the ASAS-European Alliance of Associations for Rheumatology recommendations and failure of ≥2 biological or targeted synthetic disease-modifying antirheumatic drugs with different mechanisms of action unless contraindicated), suboptimal disease control, and physician or patient acknowledgement of problematic signs/symptoms in patients diagnosed with axSpA by the rheumatologist. This definition represents a broad concept that includes various reasons that lead to an unsatisfactory treatment outcome. TR axSpA is covered by the D2M definition but requires a history of treatment failure, the presence of objective signs of inflammatory activity, and the exclusion of noninflammatory reasons for nonresponse. The proposed D2M definition incorporating TR disease was endorsed by ASAS at the annual meeting in January 2024, with 89% votes (109/123) in favour of it.</p><p><strong>Conclusions: </strong>The ASAS D2M axSpA definition, including TR disease, allows for identifying patients with unmet needs, paving the way for further research in this condition and its clinical care improvement.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis.","authors":"Désirée van der Heijde, Victoria Navarro-Compán, Robert Landewé, Joachim Sieper, Floris van Gaalen, Lianne S Gensler, Pedro M Machado, Helena Marzo-Ortega, Denis Poddubnyy, Mikhail Protopopov, Sofia Ramiro, Alexandre Sepriano, Xenofon Baraliakos","doi":"10.1016/j.ard.2025.01.003","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.003","url":null,"abstract":"<p><strong>Objective: </strong>To describe the role of the Assessment of SpondyloArthritis interntational Society (ASAS) over the past 30 years in the understanding of the field of spondyloarthritis.</p><p><strong>Methods: </strong>A narrative review of the achievements.</p><p><strong>Results: </strong>A summary of the role of ASAS in defining nomenclature, definition of and criteria for SpA, outcome assessments, recommendations, and education.</p><p><strong>Conclusion: </strong>ASAS played an important role in shaping the field of SpA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}